SRRK
Next earnings: Aug 5, 2026 · Before open
Signal
Mixed11
Price
1
Move-3.76%Selling pressure
Volume
1
Volume0.9× avgNormal activity
Technical
1
RSIRSI 60Momentum positive
PRICE
Prev Close
51.28
Open
50.51
Day Range48.95 – 51.39
48.95
51.39
52W Range27.07 – 51.63
27.07
51.63
91% of range
VOLUME & SIZE
Avg Volume
1.5M
FUNDAMENTALS
P/E Ratio
-14.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.45
Market-like
Performance
1D
-3.76%
5D
+6.36%
1M
+0.06%
3M
+7.33%
6M
+31.92%
YTD
+12.03%
1Y
+60.07%
Best: 1Y (+60.07%)Worst: 1D (-3.76%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 8.6 · FCF negative
Neutral
Key MetricsTTM
Market Cap$5.91B
Revenue TTM$0.00
Net Income TTM-$408.73M
Free Cash Flow-$303.86M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-163.5%
Return on Assets-76.4%
Debt / Equity0.75
Current Ratio8.64
EPS TTM$-3.21

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
46/100
Liquidity
8.64Strong
Leverage
0.75Strong
Coverage
-55.5xConcern
ROE
-163.5%Concern
ROIC
-85.0%Concern
Cash
$324MStrong
ANALYST COVERAGE12 analysts
BUY
+19.6%upside to target
L $55.00
Med $59.00consensus
H $65.00
Buy
12100%
12 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
RSI RangeRSI 60 — Bullish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 8.64 — healthy liquidity
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 20, 2026
In 95 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 15.5%

+6.4% vs SMA 50 · +22.9% vs SMA 200

Momentum

RSI59.5
Positive momentum, not extended
MACD+0.91
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$51.63+4.6%
Current
$49.35
EMA 50
$47.16-4.4%
EMA 200
$40.73-17.5%
52W Low
$27.07-45.1%
52-Week RangeNear 52-week high
$27.0791th %ile$51.63
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:2
Dist days:3
Edge:+1 dist
Volume Context
Avg Vol (50D)1.5M
Recent Vol (5D)
1.5M-2%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 13 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$153846
$147157$160534
-$3.44
±5%
High10
FY2026(current)
$6.4M
$1.5M$14.6M
+4074.1%-$3.19
±20%
High12
FY2027
$156.1M
$114.5M$195.5M
+2330.5%-$2.49
±18%
High13
Range confidence:Tight (high)ModerateWide (low)
Earnings HistorySRRK
Last 8Q
-9.5%avg beat
Beat 1 of 8 quartersMissed 5 Estimates falling
+2%
Q3'24
-14%
Q4'24
Q1'25
-6%
Q2'25
-48%
Q3'25
-8%
Q4'25
Q1'26
-1%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
JefferiesBuy
Oct 24
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Woods KeithCOO
$507K
Apr 16
SELL
Vaishnaw AkshayDir
$607K
Apr 16
SELL
Sinha VikasCFO
$516K
Apr 16
SELL
Hallal DavidCEO
$1.5M
Apr 16
SELL
Qatanani MoCHIEF SCIENTIF…
$349K
Feb 23
SELL
Qatanani MoCHIEF SCIENTIF…
$41K
Feb 23
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
FMR LLC
17.2M
2
Siren, L.L.C.
10.8M
3
Redmile Group, LLC
9.1M
4
BlackRock, Inc.
7.5M
5
Samsara BioCapital, LLC
6.9M
6
WELLINGTON MANAGEMENT GROUP LLP
6.7M
7
PRICE T ROWE ASSOCIATES INC /MD/
6.2M
8
Orbis Allan Gray Ltd
4.2M
News & Activity

SRRK News

About

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Nagesh Mahanthappa
Country
United States
Vikas SinhaCFO & Treasurer
Ryan IarrobinoSenior Vice President of Clinical Development & Operations
Rushmie NofsingerVice President of Corporate Affairs & Investor Relations
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
SRRK
$49.35-3.76%$5.9B1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.30%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-3.08%50.3+398824.8%-4085.6%1500